기능성 소화불량증 환자에서 mosapride의 상부 위장관 증상 및 위배출능에 대한 효과

Abstract

Background/Aims: Mosapride is a new, prokinetic, 5-HT4 agonistic agent free of dopamine D2 receptor antagonist properties. The aim of this study was to evaluate the effects of mosapride on upper GI symptoms and gastric emptying in patients with functional dyspepsia. Methods: Eighty-one patients were randomly allocated to treatment with mosapride (5 mg t.i.d) (n=42) or domperidone (10 mg t.i.d) (n=39) in a single-blind, prospective, multicenter study. The changes in gastric emptying and symptom severity score after 2-week treatment were evaluated for the treatment efficacy. Results: The proportion of patients with symptom improvement more than 50% after medications was 84.6% in the mosapride-treated group and 80.6% in the domperidone-treated group, and this difference was not significant ( p=0.6426). In both groups, gastric emptying measured at 120 minutes after test meal was significantly accelerated after 2-week treatment compared with that of baseline. However, there was no significant difference between te two groups after 2-week treatment. Mosapride was well tolerated, and no serious adverse events were observed. Conclusions: Mosapride is a safe and useful drug for the treatment of patients with functional dyspepsia.